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Introduction
Ovarian cancer is the main reason of death from 
gynaecological malignant tumors, worldwide. Although 
there are advanced improvements in surgical techniques 
and accurately designed chemotherapy regimens, 
reversion remains practically unavoidable in patients 
with progressive disease.
1,2
 Ovarian cancer is the fifth 
cause of death related to the cancer in women and covers 
a histologically and genetically a wide range of 
malignancies, containing those of epithelial, sex cord-
stromal and germ cell source.
3
 In the year 2016, about 
22,280 new cases with ovarian cancer were diagnosed 
and approximately 14,240 women died because of this 
cancer in the United States.
4
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Abstract 
Purpose: Ginger is a natural compound with anti-cancer properties. The effects of ginger 
and its mechanism on ovarian cancer and its cell line model, SKOV-3, are unclear. In this 
study, we have evaluated the effect of ginger extract on SKOV-3.  
Methods: SKOV-3 cells were incubated with ginger extract for 24, 48 and 72 hours. Cell 
toxicity assay was performed. Different data mining algorithms were applied to highlight 
the most important features contributing to ginger inhibition on the SKOV-3 cell 
proliferation. Moreover, Real-Time PCR was performed to assay p53, p21 and bcl-2 genes 
expression. For co-expression meta-analysis of p53, mutual ranking (MR) index and 
transformation to Z-values (Z distribution) were applied on available transcriptome data in 
NCBI GEO data repository.  
Results: The ginger extract significantly inhibited cancer growth in ovarian cancer cell line. 
The most important attribute was 60 µg/ml concentration which received weights higher 
than 0.50, 0.75 and 0.95 by 90%, 80% and 50% of feature selection models, respectively. 
The expression level of p53 was increased sharply in response to ginger treatment. Systems 
biology analysis and meta-analysis of deposited expression value in NCBI based on rank of 
correlation and Z-transformation approach unraveled the key co-expressed genes and co-
expressed network of P53, as the key transcription factor induced by ginger extract. High 
co-expression between P53 and the other apoptosis-inducing proteins such as CASP2 and 
DEDD was noticeable, suggesting the molecular mechanism underpinning of ginger action.  
Conclusion: We found that the ginger extract has anticancer properties through p53 
pathway to induce apoptosis.  
Research Article 
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There are different kinds of ovarian cancer depend on 
where the cell type originated. Epithelial cell ovarian 
cancer (EOC), gonadal-stromal, and germ cell make 
90%, 6% and 4% incidence of ovarian cancer in 
patients, respectively. Epithelial ovarian cancer is 
derived from the celomic epithelium or mesothelium 
(epithelial ovarian carcinoma) and others arise from 
primordial germ cells, ovarian stromal or mesenchyme 
and sex cord.
5-7
 Some factors are associated with a 
high risk of ovarian cancer, such as old age, nuliparity, 
family history, infertility and endometriosis; on the 
other hand, factors such as usage of oral 
contraceptives, salpingo-oopherectomy, tubal ligation, 
hysterectomy and breast feeding are known to have a 
more protective effect.
5,7,8
  
Due to the lack of specific symptoms, the most ovarian 
cancers are diagnosed in the advanced stages. Therefore, 
the cost of treatment is high and prognosis is poor.
5
 The 
majority of women whose diseases are at high risk 
(poorly differentiated or presence of malignant cells in as 
cites fluid) benefit from postoperative chemotherapy. 
Combination chemotherapy is recommended for these 
patients.
8
 Chemotherapy is useful as an adjunct to 
surgery in some types of ovarian cancers and may be 
curative. Unfortunately, some factors such as severe 
disability, old age, malnutrition or direct organ 
involvement by primary or metastatic cancer influence 
the incidence of severe side effects of chemotherapy; 
therefore, using traditional medicine with chemotherapy 
not only kills cancer cells but also limits the cancer side 
effects. Ginger is from the rhizome of Zingiber officinale 
that has been used in traditional medicine for a long 
time.
9
 
Great progresses in biotechnology and molecular 
biology have been caused the understanding of the 
genetics and molecular basis of disease which can help 
to find strategic therapeutic approaches and novel 
targeted therapies to manage ovarian cancer. Therefore, 
it might be possible to choose medications based on the 
molecular characteristics of tumors and also as basis of 
personalized medicine. Numerous experimental studies 
have been conducted in the chemo preventive 
belongings of ginger and their mechanisms. Their main 
focus is on antioxidant, neuroprotection, proliferation 
suppression, cancer prevention, pro-apoptotic and anti-
inflammatory activities.
10-16
 The result of a study on the 
major extracts of ginger shows that 6-gingerol inhibits 
angiogenesis in the human endothelial cells, it also 
down-regulates cyclin D1 and causes cell cycle arrest in 
the G1 phase.
17
 In addition, 6-gingerol plays a rule in 
oxidative stress, DNA damage, G2/M cell cycle arrest 
and also it induces autophagy and activates tumor 
suppressor proteins including P53 and P21.
18
 Despite 
the anticancer activity of ginger, its mechanisms are 
still poorly understood.  
This study focuses on the effects of the ginger 
extraction on human ovarian cancer cell line (SKOV-3) 
to find out if the new ginger extraction is effective in 
treatment of ovarian cancer. In addition, bioinformatics 
analysis was applied on these datasets to highlight the 
most important features contribute to ginger inhibition 
on the SKOV-3 cell proliferation. The expression of 
p21 (cyclin-dependent kinase inhibitor 1), p53 (tumor 
suppressor gene), and Bcl-2 (B-cell lymphoma 2) genes 
following ginger treatment have been investigated. 
Also, Systems biology analysis and meta-analysis of 
deposited expression value in NCBI based on rank of 
correlation and Z-transformation approach were applied 
for further investigations about effect of ginger extract 
treatment on ovarian cancer cell line.  
 
Material and Methods 
Cell culture  
SKOV-3, human epithelial ovarian cancer cell line was 
purchased from Pasteur Institute Cell Bank of Iran. The 
cells were grown as monolayer in 25 cm
2 
flask (Orange 
Scientific) with culture medium (DMEM) (Sigma; 
Chemical Co., St. Louis, MO, USA) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Gibco- 
Life technologies), streptomycin (100 μg/mL), penicillin 
(100 units/mL) (Sigma), and cultured under standard 
condition at 37°C in a 5% humidified CO2 incubator. The 
medium was exchange twice a week. 
 
Cell proliferation assay  
The effect of ginger inhibition on the SKOV-3 cell 
proliferation was determined by MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-DiphenyltetrazoliumBromide) 
assay. The cells were seeded in 96-well tissue culture 
plates at a density of 3500 cells per well and incubated 
at 37 °C and 5% CO2 humidified incubator. After 50% 
confluency, the cells were treated with the ginger 
extract (Sigma-Aldrich., W252108) in different 
concentrations and incubated for 24, 48 and 72 hours in 
assorted plates. Following the appropriate times, the 
upper medium was removed and 0.5 mg/ml of MTT 
(Sigma) solution (PBS and medium) was added to each 
well and incubated for 4h at 37°C. The medium was 
removed and the blue formazan crystals were dissolved 
in 100μl of DMSO. The absorbance was read in a 
microplate reader (Biotek, model Elx808) at 570 nm. 
Each experiment was repeated in triplicate format, and 
results were expressed as means ± SEM. 
 
Attribute weighting 
As described before the inhibitory effects of ginger 
extracts on the SKOV-3 cell proliferation were 
determined by MTT assay. MTT assay was performed 
as described above. The absorbance was read by a 
microplate reader at 570 nm. Each experiment was 
repeated in triplicate format. In order to identify the 
most important attributes and to find the possible 
patterns in features which determine the effect of ginger 
inhibition on the SKOV-3 cell proliferation by MTT, 10 
different algorithms of weighting models were applied 
on the datasets. Dataset imported into software 
(RapidMiner 5.0.001, Rapid-I GmbH, Stochumer Str. 
475, 44,227 Dortmund, Germany). The attribute 
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weighting models were: weight by information gain, 
weight by information gain ratio, weight by rule, 
weight by deviation, weight by chi squared statistic, 
weight by Gini index, weight by uncertainty, weight by 
relief, weight by principal component analysis (PCA), 
and weight by Support Vector Machines (SVM). The 
algorithms definitions have already been described in 
our previous paper.
19
 Weights were normalized into the 
interval between 0 and 1 to allow the comparison 
between different methods. 
 
Decision Tree Models 
Decision tree algorithms provide visual explanation of 
the most important features through depicting an 
inverted tree with the most important feature as root 
and other variables as leaves. Various decision trees 
including Random Forest, Decision Stump Decision, 
Iterative Dichotomiser 3 (ID3), CHi-Squared Automatic 
Interaction Detection (CHAID) and Random Tree were 
applied on dataset. Details of each decision tree model 
have also been presented before.
19
  
 
RNA extraction and c-DNA synthesis  
SKO-V cells were seeded 300000 cells per 6 well. After 
one day, the cells were treated with 30 μg/ml ginger 
extract. Forty-eight hours after treatment, the upper 
medium was removed from monolayer cancer cells and 
scrapped in 1 ml RNAX-PLUS (Cinagene, Iran). RNA 
was completely extracted from samples using Cinagene 
Kit based on the manufacturer’s instruction (RNX-Plus 
Solution, SinaClon, Iran). After purification and 
quantification, RNA was determined by measuring 
optical density at 260 and 280 nm by nanodrop 
(NanoDrop- ND-1000). The cDNA synthesis was 
performed according to cDNA syntheses kit instruction 
(Qiagene).  
 
Real-time PCR  
Real-time PCR was carried out to detect mRNA 
expression
20
 with some modifications. p53, p21 and bcl-
2 mRNA expression were investigated using Cycler IQ5 
Multicolor Real-time PCR Detection System (Bio-Rad, 
USA). For various mRNA, first-strand cDNA was 
amplified using P53, p21 and bcl2 primers as described 
in the Table 1. β-actin was used as housekeeping gene. 
Each experiment was repeated in triplicate format, and 
the results were expressed as means ±SEM.  
 
Statistics  
Statistical analysis was performed with SPSS version 16.0 
software and ANOVA test was used to compare between 
groups. Data are represented as Mean ± SEM. The 
differences were considered significant when *P<0.05. 
 
Co-expression based meta-analysis and co-expression 
network construction 
For co-expression meta-analysis of p53 (Tp53), mutual 
ranking (MR) index and transformation to Z-values (Z 
distribution) were applied on available transcriptome 
data in NCBI GEO, as previously described.
21
 MR index 
is a more reliable index in meta-analysis, compared to 
Pearson correlation coefficient, as it is based on rank of 
correlation and geometric average of the Pearson 
correlation coefficient rank.
22
 Geometric average is a as 
correlation coefficient are raked in logarithmic manner.
22
 
Lower amount of MR implies higher correlation and a 
more strong expression association. To perform co-
expression meta-analysis, the deposited transcriptome 
data in NCBI GEO NCBI were subjected to MR and Z-
transformation using COXPRESSdb.
23
 to identify the top 
100 co-expressed genes with p53 transcription factor 
with low MR. Calculated MR associations, as meta-
analysis co-expression measurement, were used for 
construction of co-expression network. 
 
Table 1. Primers used for Real time- PCR 
Gens Genes Primer sequence (5’ to 3’) 
P53 
Forward:GTTCCGAGAGCTGAATGAGG 
Reverse: ACTTCAGGTGGCTGGAGTGA 
P21 
Forward: GCTTCATGC CAG CTACTTCC 
Reverse: CCCTTCAAAGTG CCATCTGT 
Bcl-2 
Forward: GTCATGTGTGTGGAGAGCGT 
Reverse: ACAGTTCCACAAAGGCATCC 
β-actin 
Forward: CCTTCCTTCCTGGGCATG 
Reverse: TCCTGTCGGCAATGCCAG 
 
Results  
The effect of ginger on cellular proliferation 
In order to determine the effect of ginger on the SKOV-3 
cell lines proliferation, MTT assay was illustrated at 24, 
48 and 72 hours after ginger treatment. As shown in 
Figure 1 and 2 cell growth was inhibited considerably by 
ginger; consequently, it can be seen in figures, cell 
proliferation was decreased to 50% (P<0.05) after 48 and 
72 hours of treatment. The results from analysis of the 
data for cell viability assay via MTT demonstrated that at 
24h, 48h and 72h time points, the IC50 of ginger for 
SKOV-3 was approximately 97 µg/ml, 60 µg/ml and 40 
µg/ml. respectively. 
 
Attribute weighting 
Following normalization, 10 different attribute 
weighting models (as described in material and 
methods) were applied on GAD and RSD datasets. 
Each attribute was weighted between 0 and 1. These 
weights determined the importance of attributes in 
effect of new ginger extract concentration on SKOV3 
cancer cell line. Attributes which gained weight equal 
to 0.5 or higher by at least five weighting models were 
selected. Table 2 shows the most important attributes 
was 70µg/ml concentration which received weights 
higher than 0.50, 0.75 and 0.95 by 90%, 80% and 50% 
feature selecting models. Concentration of 60µg/ml and 
50µg/ml variables were the second and third important 
features, while 40 µg/ml concentration granted the 
lowest weights by attribute weighting algorithms. 
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Figure 1. MTT assay was used to assess the effects of ginger in 
the Proliferation of SKOV-3 Ovarian Cancer Cell Line after 24h 
and 48h. There are significant differences between treated cells 
and controls (P<0.05)*. 
 
 
Figure 2. MTT assay was used to assess the effects of ginger 
on the Proliferation of SKOV-3 Ovarian Cancer Cell Line after 
72h. There are significant differences between treated cells and 
controls (P<0.05)*. 
Table 2. 10 different algorithms of weighting models applied on the datasets and new generated datasets 
PCA SVM Relief Uncertainty 
Gini 
Index 
Chi 
Squared 
Deviation Rule 
Info Gain 
Ratio 
Info 
Gain 
Attribute 
Count 
0.50 
Count 
0.75 
Count0.95 
.79 1.00 .26 .68 1.00 1.00 .80 1.00 1.00 1.00 70µg/ml 9 8 5 
.66 .84 .23 1.00 1.00 1.00 .59 1.00 1.00 1.00 50 µg/ml 9 7 5 
.86 .65 .40 .68 1.00 1.00 .82 1.00 1.00 1.00 80 µg/ml 9 7 4 
1.00 .61 .30 .51 1.00 1.00 1.00 1.00 1.00 1.00 60 µg/ml 9 7 6 
.66 .68 .38 1.00 1.00 1.00 .60 1.00 1.00 1.00 90 µg/ml 9 6 5 
.53 .72 .39 1.00 1.00 1.00 .44 1.00 1.00 1.00 100µg/ml 8 6 5 
.37 .66 .34 .76 1.00 1.00 .26 1.00 1.00 1.00 110µg/ml 7 6 4 
.31 .46 .22 .76 1.00 1.00 .23 1.00 1.00 1.00 120µg/ml 6 6 4 
.44 .37 .00 .37 1.00 1.00 .36 1.00 1.00 1.00 40µg/ml 5 5 4 
.00 .00 1.00 .00 .00 .00 .00 1.00 .00 .00 control 2 2 2 
 
Tree induction algorithms also underlined the 
significance of features that weighed most in weighting 
models. Remarkably, decision tree models appointed the 
same features selected by attribute weighting as the root 
features to build the trees, as can be seen in Figure 3. The 
trees were just single branches showing the selected 
features were so decisive that can be used as cut off 
criteria. 
 
 
Figure 3. Decision Tree algorithm applied on datasets with Gini 
Index criterion 
 
P53, P21 and Bcl-2 genes expression in SKOV-3 cells 
were investigated using RT-PCR analysis (Figurer 4). 
The genes Ct values were normalized against mRNA 
level of β-actin as the housekeeping gene and the relative 
expression for each group was measured. After 48 hours 
of ginger treatment, the level of p53 expression was 
increased.  
 
 
Figure 4. Real Time PCR Analysis: All of data were normalized 
to β-actin gene expression: Increase in P53 genes expression 
following ginger (30 μg/ml) treatment following 48h treatment. 
 
Co-expression based meta-analysis of p53 (Tp53) and 
its co-expression network  
Among the studied tumor repressor genes, p53 was the 
top highly upregulated transcription factor in response to 
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ginger extract, additional systems biology and meta-
analysis were performed to unravel possible involved 
mechanism of ginger action through p53. Here, rank of 
correlation value was used rather than correlation value 
due to its reliability in meta-analysis. The top 100 co-
expressed genes with p53 (Tp53) sorted based on low 
MR are presented in Table 3. The co-expression 
network, derived based on calculated association 
coefficients, are presented in Figure 5.  
 
Table 3. The top 100 co-expressed genes with p53 (Tp53) sorted based on low mutual ranking (MR) index are presented. Meta-analysis 
using transcriptomic data in NCBI GEO was used for co-expression meta-analysis. When a gene list is repeatedly observed in 
indipendent platforms, the coexpressed gene list can be regarded as reliable with high supportability (value=3). 
Rank Gene Function 
Entrez 
Gene ID 
Supportability 
MR for TP53 
association 
0 TP53 tumor protein p53 7157 
 
0 
1 YWHAE 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon 
7531 1 4 
2 RBM14 RNA binding motif protein 14 10432 1 15.9 
3 DNAJC14 DnaJ (Hsp40) homolog, subfamily C, member 14 85406 1 20.4 
4 APH1A APH1A gamma secretase subunit 51107 2 41.7 
5 NONO non-POU domain containing, octamer-binding 4841 3 42.5 
6 RBBP4 retinoblastoma binding protein 4 5928 2 43.4 
7 TAPBP TAP binding protein (tapasin) 6892 3 44 
8 SENP3 SUMO1/sentrin/SMT3 specific peptidase 3 26168 3 45 
9 RXRB retinoid X receptor, beta 6257 2 45.5 
10 MAT2A methionine adenosyltransferase II, alpha 4144 1 46.3 
11 DEDD death effector domain containing 9191 3 49.1 
12 MAZ MYC-associated zinc finger protein (purine-binding transcription factor) 4150 3 49.1 
13 FKBP1A FK506 binding protein 1A, 12kDa 2280 3 51 
14 C21orf33 chromosome 21 open reading frame 33 8209 3 59.2 
15 WDR1 WD repeat domain 1 9948 3 61.2 
16 LRRC41 leucine rich repeat containing 41 10489 2 62.7 
17 COLGALT1 collagen beta(1-O)galactosyltransferase 1 79709 3 64.7 
18 ARHGAP1 Rho GTPase activating protein 1 392 1 72.5 
19 KDELR1 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 1 
10945 3 73.1 
20 CALR calreticulin 811 2 74.2 
21 GLE1 GLE1 RNA export mediator 2733 2 75.9 
22 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 396 3 77.8 
23 PATZ1 POZ (BTB) and AT hook containing zinc finger 1 23598 2 78.6 
24 PRR14 proline rich 14 78994 2 80 
25 RAB11B RAB11B, member RAS oncogene family 9230 3 84.5 
26 SMARCC1 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
6599 3 84.7 
27 NFYC nuclear transcription factor Y, gamma 4802 1 85 
28 FLOT2 flotillin 2 2319 3 88.6 
29 STYX serine/threonine/tyrosine interacting protein 6815 2 88.7 
30 PPP5C protein phosphatase 5, catalytic subunit 5536 2 95.2 
31 TMEM259 transmembrane protein 259 91304 3 96.1 
32 EIF5A eukaryotic translation initiation factor 5A 1984 3 97.6 
33 PPP2R5D protein phosphatase 2, regulatory subunit B', delta 5528 2 98.3 
34 MYBBP1A MYB binding protein (P160) 1a 10514 3 101.4 
35 PTBP1 polypyrimidine tract binding protein 1 5725 2 103 
36 PHF23 PHD finger protein 23 79142 3 103.6 
37 EXOSC6 exosome component 6 118460 1 104.7 
38 GTF2I general transcription factor IIi 2969 1 105.4 
39 ZNF672 zinc finger protein 672 79894 2 107.1 
40 TRRAP transformation/transcription domain-associated protein 8295 3 107.3 
41 CFL1 cofilin 1 (non-muscle) 1072 3 107.5 
42 SAFB scaffold attachment factor B 6294 3 107.8 
43 MPDU1 mannose-P-dolichol utilization defect 1 9526 3 108.3 
44 TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) 56993 2 108.4 
45 MRPL38 mitochondrial ribosomal protein L38 64978 3 109.6 
46 MTMR1 myotubularin related protein 1 8776 1 112.2 
47 SRSF1 serine/arginine-rich splicing factor 1 6426 3 112.6 
48 PFN1 profilin 1 5216 3 114.5 
49 EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa 1968 3 115 
50 FARSA phenylalanyl-tRNA synthetase, alpha subunit 2193 3 116.6 
51 LAMP1 lysosomal-associated membrane protein 1 3916 3 118.4 
52 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H) 3187 3 123.3 
53 STIP1 stress-induced phosphoprotein 1 10963 2 130.9 
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Rank Gene Function 
Entrez 
Gene ID 
Supportability 
MR for TP53 
association 
54 HSF1 heat shock transcription factor 1 3297 3 135.6 
55 GANAB glucosidase, alpha; neutral AB 23193 3 135.7 
56 ASB16-AS1 ASB16 antisense RNA 1 339201 2 136 
57 LIX1L Lix1 homolog (chicken) like 128077 3 136.8 
58 KLHDC3 kelch domain containing 3 116138 3 137.2 
59 DRG2 developmentally regulated GTP binding protein 2 1819 3 139 
60 BANF1 barrier to autointegration factor 1 8815 3 139.8 
61 AKIRIN2 akirin 2 55122 1 140.8 
62 RELA v-rel avian reticuloendotheliosis viral oncogene homolog A 5970 3 141.5 
63 CASP2 caspase 2, apoptosis-related cysteine peptidase 835 2 145.9 
64 MAP2K2 mitogen-activated protein kinase kinase 2 5605 3 146.8 
65 RANGAP1 Ran GTPase activating protein 1 5905 3 150.6 
66 NAP1L4 nucleosome assembly protein 1-like 4 4676 2 151.7 
67 MTA1 metastasis associated 1 9112 3 154.1 
68 REPIN1 replication initiator 1 29803 2 154.3 
69 ZBTB45 zinc finger and BTB domain containing 45 84878 3 155.4 
70 PPP2R1A protein phosphatase 2, regulatory subunit A, alpha 5518 3 156.1 
71 CYB5R3 cytochrome b5 reductase 3 1727 2 157.6 
72 UBE4B ubiquitination factor E4B 10277 1 159.4 
73 ACLY ATP citrate lyase 47 3 160.4 
74 UBE2G2 ubiquitin-conjugating enzyme E2G 2 7327 0 163.2 
75 DNAAF5 dynein, axonemal, assembly factor 5 54919 3 170 
76 GDI2 GDP dissociation inhibitor 2 2665 3 170.1 
77 BSG basigin (Ok blood group) 682 3 171.8 
78 SLC25A11 
solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), 
member 11 
8402 3 173.4 
79 BTBD2 BTB (POZ) domain containing 2 55643 3 173.7 
80 C1orf174 chromosome 1 open reading frame 174 339448 2 176.2 
81 ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 4363 3 178.4 
82 DCAF15 DDB1 and CUL4 associated factor 15 90379 2 180.4 
83 SLC29A1 
solute carrier family 29 (equilibrative nucleoside transporter), member 
1 
2030 2 181 
84 KCTD5 potassium channel tetramerization domain containing 5 54442 1 191.8 
85 TBC1D5 TBC1 domain family, member 5 9779 2 192.7 
86 SHC1 SHC (Src homology 2 domain containing) transforming protein 1 6464 3 192.9 
87 CRTAP cartilage associated protein 10491 2 194.3 
88 NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 64710 3 197.2 
89 STAT2 signal transducer and activator of transcription 2, 113kDa 6773 3 198.6 
90 NFRKB nuclear factor related to kappaB binding protein 4798 2 200.8 
91 ANKFY1 ankyrin repeat and FYVE domain containing 1 51479 3 207.5 
92 TRAPPC1 trafficking protein particle complex 1 58485 3 208 
93 CBFB core-binding factor, beta subunit 865 2 210 
94 NCOA5 nuclear receptor coactivator 5 57727 3 211.2 
95 GLYR1 glyoxylate reductase 1 homolog (Arabidopsis) 84656 2 213.7 
96 HNRNPU 
heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor 
A) 
3192 3 213.9 
97 NUCB1 nucleobindin 1 4924 3 214.7 
98 NUMA1 nuclear mitotic apparatus protein 1 4926 3 216.3 
99 CTNND1 catenin (cadherin-associated protein), delta 1 1500 3 216.6 
100 CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 1495 2 217.2 
 
YWHAE (tyrosine 3-monooxygenase) was the top co-
expressed genes with P53 according to meta-analysis 
(Table 3, Figure 5). Interestingly, two apoptosis inducing 
genes, including DEDD (death effector domain 
containing) and CASP2 (caspase 2, apoptosis-related 
cysteine peptidase) are highly co-expressed with P53 
which can be induced after ginger application. Based on 
normalized meta-data derived from expression data of 
different tissues and cell lines in NCBI GEO 
(Supplementary 1 and Supplementary 2), we calculated 
the Pearson correlation, in addition to MR. Highly 
positive and significant correlation was observed 
between P53 and CASP2 (Pearson correlation = 94.1%, 
P-Value = 0.000) and also P53 and DEDD (Pearson 
correlation = 90%, P-Value = 0.000). 
 
Discussion 
In this study, we investigated the effects of the ginger 
extract on ovarian cancer cell line and used 
bioinformatics analysis to find out the most accurate and 
reliable results. Ginger (Zingiber officinale), a natural 
poly-phenol constituent from rhizomes and ginger root, 
is extensively used as a spice or a traditional medicine. 
Researchers have been consistently revealed anti-cancer 
activities of phenolic substance in vegetables and fruits 
both in vitro and in vivo.
17,24-27
 Recently, different 
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publications reveled the anticancer effect o f  ginger on 
various human cancer cell lines such as breast cancer 
(BC), prostate adeno-carcinoma (PC-3), Hela (Human 
cervical cancer), lung non-small cancer (A549), and 
colon cancer.
28-32
 Weng and the colleagues reported that 
6-Shogaol and 6-gingerol efficiently block invasion and 
metastasis of hepatocellular carcinoma by different 
molecular mechanisms.
26
  
 
 
Figure 5. Co-expression network of Tp53, ginger associated 
transcription factor, derived from co-expression meta-analysis of 
Tp53 in transcriptomic data of NCBI GEO.  
 
Our studies by MTT assay illustrated that the ginger 
extract displayed strong cytotoxicity effects on ovarian 
cancer cell line, SKOV-3. Attribute weighting 
algorithms weighs the importance of each attribute in 
distinguishing between different concentrations of 
ginger; the results showed a few ranges of 
concentrations, from 50µg/ml to 80µg/ml, gained the 
highest possible weights and this range can be used to 
find the best concentration in lab works. Decision tree 
models also confirmed the above findings and clearly 
showed that these concentrations are playing crucial 
roles in suppressing SKOV-3 cancer cell line toxicity.  
In order to normal cells are transformed into a fully 
malignant cancer cells, a set of genetic and epigenetic 
alterations must be occurred.
33
 Genes associated with 
cell death program is considered crucial for the 
appropriate function and development of most 
mammalian organisms. BCL-2 (B-Cell Lymphoma 2), a 
member of the human Bcl-2 family is one of the main 
anti-apoptotic genes and seems to be a good target for 
cancer therapy in the future. They control the status of 
unreturnable for clonogenic cell survival and thereby 
affect tumorigenesis and host–pathogen interactions 
and also regulate animal development.
34-36
 Today’s 
clinical trials which target Bcl-2 family proteins or 
mRNA are giving hopes for discovering a new group of 
anticancer drugs.
37
 Our studies demonstrated that Bcl-2 
has more than 0.4-fold reduction in expression after 48 
hours ginger treatment compared to control group. 
Previously, Wang and colleagues in 2002 demonstrated 
6-gingerol effects on apoptosis induction and inhibition 
of Bcl-2 expression in promyelocytic leukemia HL-60 
cell.
38
 
Furthermore, we investigated tumor suppressor p53 
and cyclin-dependent kinase inhibitor 1 p21 genes in 
this study to find out their role in SKOV-3 cell death 
after ginger therapy. In many cell types, inactivation of 
the p53 gene is the most common alternation explained 
in ovarian cancer.
39,40
 P53 is involved in some cell 
pathways such as cell cycle arrest, apoptosis, 
metastasis, invasion, stem cell maintenance, 
metabolism, cell cycle and DNA repair.
41-43
 Moreover, 
P53-target genes play important roles in cell cycle 
arrest (e.g., p21) and apoptotic (e.g.; Bax) pathway.
44
 
p21 is expressed by both p53-dependent and 
independent mechanisms after stress.
45
 In cell cycle 
arrest pathway, p53 affects p21 expression, thus p21 
stimulation inhibits tumor development and causes cell 
arrest;
45,46
 however, it can be activated independently 
and can have cancer-promoting properties.
47
 Therefore, 
the control of p53's transcriptional activity is critical 
for novel therapeutic approaches to design drugs for 
ovarian cancer treatment.
47,48
 
Our result showed that the level of p53 expression in 
the ginger extract treated ovarian cancer cell line was 
increased about 7-fold compared to the control group 
(Figure 4). On the other hand, the level of p21 
expression was decreased after drug treatment., 
Therefore, it could be understood that p53 might 
regulate the cell death in other pathway. Besides, p53 
regulates transcription of apoptotic target genes such as 
Bcl-2 and Bax.
49
 Our results revealed bcl-2 gene 
expression decreased in ginger treated cells, so p53 
might stimulate apoptosis through bcl-2 elimination. 
Additional, Systems biology analysis and meta-analysis 
of deposited expression value in NCBI based on rank of 
correlation and Z-transformation approach unraveled 
the key co-expressed genes and co-expressed network 
of P53, as the key transcription factor induced by ginger 
extract. High co-expression between P53 and the other 
apoptosis-inducing proteins such as CASP2 and DEDD 
was noticeable, suggesting the molecular mechanism 
underpinning of ginger action. 
 
Conclusion 
Our study revealed that p53 expression is the main 
reason for the cytotoxicity effects of ginger in ovarian 
cancer cells and the cause of cell death in SKOV-3 
cells. Bioinformatics analysis help to confirm and get 
more accurate and reliable results driven from ginger 
effect on the cell line and p53 expression. The data 
outlined the key co-expressed genes and co-expressed 
network of P53, as the key transcription factor induced 
by ginger extract. 
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It could be suggested that p53 in new ginger extract 
treated ovarian cancer cell line stimulates tumor 
suppression through apoptosis, rather than cell cycle 
arrest. 
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